Traders should monitor the AACR presentation on April 22 for further validation of the platform's applicability in hard-to-treat cancers. Positive reception could catalyze investor interest and potential partnership discussions, supporting re-rating potential despite current small market cap.
Price Chart
Executive Summary
Evaxion A/S announced new preclinical data demonstrating the scalability of its AI-Immunology platform in glioblastoma, identifying endogenous retrovirus (ERV)-derived antigens as a novel target source for personalized cancer vaccines. The data, to be presented at the AACR Annual Meeting on April 22, 2026, supports a proof-of-concept for overcoming low mutational burden in glioblastoma—a key challenge in immunotherapy.
Key Facts
- New data shows AI-Immunology platform can identify ERV-derived antigens in glioblastoma tumors, a novel target source absent in normal tissue.
- Platform also identified sufficient-quality neoantigens in the majority of patients, enabling personalized vaccine design.
- Proof-of-concept includes bioinformatic and experimental data showing immunologic responses to ERV antigens.
- Data to be presented at AACR Annual Meeting on April 22, 2026, enhancing scientific and potential partner visibility.
- Collaboration with Duke University School of Medicine adds credibility to findings.
Financial Impact
No direct financial impact disclosed; potential long-term value creation through platform validation and partnership opportunities.
Risk Factors
- Preclinical nature of data — not yet validated in clinical trials.
- Glioblastoma vaccine development remains high-risk and early-stage.
- No guarantee of successful commercialization or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002531 |
| Document: f6k_041726.htm | 0001171843-26-002531 |
| Document: 0001171843-26-002531-index-headers.html | 0001171843-26-002531 |
| Document: 0001171843-26-002531-index.html | 0001171843-26-002531 |
| Document: 0001171843-26-002531.txt | 0001171843-26-002531 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access